EMISPHERE TECHNOLOGIES INC
SC 13D/A, 1996-08-13
PHARMACEUTICAL PREPARATIONS
Previous: EMISPHERE TECHNOLOGIES INC, SC 13D/A, 1996-08-13
Next: EMISPHERE TECHNOLOGIES INC, SC 13D, 1996-08-13



                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                        
                                        
                                  SCHEDULE 13D
                                        
                                        
                   Under the Securities Exchange Act of 1934
                            (Amendment No.    2  )*
                                        
                          Emisphere Technologies, Inc.
                                (Name of Issuer)

                     Common Stock, par value $.01 per share
                         (Title of Class of Securities)

                                   291345106
                                 (CUSIP Number)

          Michael M. Goldberg, M.D., c/o Emisphere Technologies, Inc.,
          15 Skyline Drive, Hawthorne, New York  10532  (914) 347-2220
            (Name, Address and Telephone number of Person Authorized
                     to Receive Notices and Communications)

                                 July 31, 1996
            (Date of Event which Requires Filing of this Statement)

If the  filing person has previously filed a statement on Schedule 13G to report
the acquisition  which is  the subject  of this Schedule 13D, and is filing this
schedule because of Rule 13d-l(b)(3) or (4), check the following box  [ ].

Check the  following box  if a fee is being paid with the statement  [ ]. (A fee
is not  required only  if the  reporting person: (1) has a previous statement on
rile reporting  beneficial ownership  of more  than five percent of the class of
securities described  in Item  1; and  (2) has  filed  no  amendment  subsequent
thereto reporting  beneficial ownership  of five percent or less of such class.)
(See Rule 13d-7.)

Note:   Six copies  of this  statement, including  all exhibits, should be filed
with the  Commission.  See Rule 13d-1(a) for other parties to whom copies are to
be sent.

*The remainder  of this  cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for  any   subsequent  amendment   containing  information   which  would  alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be  "filed" for  the purpose  of Section 18 of the Securities Exchange Act of
1934 ("Act")  or otherwise subject to the liabilities of that section of the Act
but shall  be subject  to all  other provisions  of the  Act (however,  see  the
Notes).
                                                                SEC 1746 (12-91)

                                  SCHEDULE 13D

 CUSIP No.     291345106                           Page   2    of    5  Pages

      NAME OF REPORTING PERSON
 1    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
        
        Michael M. Goldberg, M.D.


      CHECK THE APPROPROPRIATE BOX IF A MEMBER OF A GROUP*        (a)[ ]
 2                                                                (b)[ ]


      SEC USE ONLY
 3


      SOURCE OF FUNDS
 4      PF  OO


      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
 5    ITEMS 2(d) OR 2(e)                                             [ ]


      CITIZENSHIP OR PLACE OF ORGANIZATION
 6      United States


                     SOLE VOTING POWER
                7     32,280
   NUMBER OF
    SHARES           SHARED VOTING POWER
 BENEFICIALLY   8     none
     OWNED
     EACH            SOLE DISPOSITIVE POWER
   REPORTING    9     32,280
    PERSON
     WITH            SHARED DISPOSITIVE POWER
                10    none


      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 11     939,777


      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
 12    SHARES*                                                        [ ]


      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 13    9.1%


      TYPE OF REPORTING PERSON
 14    IN


                     *SEE INSTRUCTIONS BEFORE FILLING OUT!
          INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
      (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.


Item 1.   Security and Issuer

     This statement relates to the Common Stock, par value $.0l per share (the
"Common Stock"), of Emisphere Technologies, Inc., a Delaware corporation (the
"Company"), with principal executive offices at 15 Skyline Drive, Hawthorne, New
York 10532.


Item 2.   Identity and Background

     This statement is filed by Michael M. Goldberg, M.D. (the "Reporting
Person"), a resident of New Jersey with a business address at 15 Skyline Drive,
Hawthorne, New York 10532.  The Reporting Person is principally employed as
Chairman of the Board and Chief Executive Officer of the Company.  The Reporting
Person (i) has not, during the last five years, been convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors) and (ii) was
not, during the last five years, a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction and as a result of such proceeding
was or is subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to, federal or
state securities laws or finding any violation with respect to such laws.  The
Reporting Person is a citizen of the United States of America.


Item 3.   Source and Amount of Funds or Other Consideration

     The Common Stock beneficially owned by the Reporting Person consists of
32,280 shares held directly (the "Held Shares") and 907,497 shares (the "Option
Shares") which the Reporting Person has the right to acquire within 60 days upon
the exercise of stock options (the "Options") granted by the Company in
connection with the Reporting Person's employment with the Company.

     The funds used to purchase the Held Shares were personal funds of the
Reporting Person.  Of the Held Shares, 26,280 shares were acquired at prices
ranging from $1.50 to $7.375 per share upon exercise of stock options granted by
the Company in connection with the Reporting Person's employment with the
Company.  Pursuant to the terms of one of such stock options, the Company loaned
the Reporting Person $7,499.63 to pay the federal income tax payable upon
exercise thereof.

     The purchase prices to acquire the Option Shares upon exercise of the
Options are (i) $9.00 per share with respect to 200,000 of the Option Shares,
(ii) $9.25 per share with respect to 20,000 of the Option shares, (iii) $8.00
per share with respect to 88,000 of the Option Shares, (iv) $8.00 per share with
respect to 12,543 of the Option Shares, (v) $12.375 per share with respect to
562,315 of the Option Shares, (vi) $1.65 per share with respect to 2,639 of the
Option Shares, (vii) $2.89 per share with respect to 1,505 of the Option Shares,
(viii) $4.40 per share with respect to 495 of the Option Shares and (ix) $8.625
per share with respect to 150,000 of the Option Shares.

     It is anticipated that the source of funds to be used in making the
purchase of the Option Shares, if the Options are in fact exercised, will be the
personal funds of the Reporting Person, the proceeds from the sale of the Held
Shares or the Option Shares or a combination of the foregoing.



Item 4.   Purpose of Transaction

     The Held Shares were acquired, and the Option Shares are beneficially
owned, by the Reporting Person for investment purposes.  The Options were
acquired by the Reporting Person as compensation in connection with the
Reporting Person's employment with the Company.  Upon continued employment with
the Company, an option (the "Unvested Option") to purchase additional shares of
the Common Stock for $8.625 per share granted to the Reporting Person in
connection with the Reporting Person's employment with the Company will become
exercisable on August 1, 2005 with respect to 600,000 shares except that the
Unvested Option will become earlier exercisable upon the occurrence of certain
other events.


Item 5.   Interest in Securities of the Issuer

(a)  The aggregate number of shares of the Common Stock beneficially owned by
the Reporting Person is 939,777, or 9.1% of the Common Stock outstanding, of
which 907,497 are the Option Shares, which the Reporting Person has the right to
acquire upon exercise of the Options.

(b)  The Reporting Person has the sole power to vote and the sole power to
dispose of the Held Shares.  Until and unless the Reporting Person exercises the
Options, the Reporting Person will have no power to vote and no power to dispose
of the Option Shares.

(c)  No transactions in the Common Stock have been effected during the past
sixty days by the Reporting Person.

(d)  No person is known to have the right to receive or the power to direct the
receipt of dividends from, or the proceeds from the sale of, any of the Common
Stock beneficially owned by the Reporting Person.

(e) Not applicable.


Item 6.   Contracts, Arrangements, Understandings or Relationships With Respect
          to Securities of the Issuer

     Pursuant to an Employment Agreement dated as of October 6, 1995 (the
"Employment Agreement") between the Reporting Person and the Company, the
Reporting Person is to serve as Chairman of the Board and Chief Executive
Officer of the Company until July 31, 2000.  In connection with the Employment
Agreement and its predecessor employment agreements, the Company granted to the
Reporting Person the Options and the Unvested Option.  Pursuant to the terms of
certain of the Options the Company is obligated to lend to the Reporting Person,
on a nonrecourse basis, the income taxes he may be required to pay upon exercise
thereof.  Such loan is to be secured by the shares of the Common Stock so
purchased and is to bear interest at the lowest possible rate to avoid
imputation of interest for federal income tax purposes.


Item 7.   Material to be Filed as Exhibits

None


                                   SIGNATURE

     After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.


                                   /s/ Michael M. Goldberg  
Dated:    August 9, 1996           Michael M. Goldberg, M.D.


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission